Heron Therapeutics
HRTX
149 hedge funds and large institutions have $115M invested in Heron Therapeutics in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 45 increasing their positions, 48 reducing their positions, and 29 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
6% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 48
7.94% less ownership
Funds ownership: 90.51% → 82.56% (-7.9%)
8% less funds holding
Funds holding: 162 → 149 (-13)
30% less capital invested
Capital invested by funds: $163M → $115M (-$48.3M)
45% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 29
67% less call options, than puts
Call options by funds: $20K | Put options by funds: $60K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAM
JW Asset Management
Miami Beach,
Florida
|
+$3.94M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$2.32M |
| 3 |
JFG
Jefferies Financial Group
New York
|
+$2.3M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.78M |
| 5 |
CC
Clearline Capital
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$7.87M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$5.9M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.05M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.93M |
| 5 |
BlackRock
New York
|
-$1.83M |
HRTX Hedge Fund Activity: Q2 2023 in Review
149 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q2 2023, worth a combined $115M — down 30% from $163M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of HRTX and 16 opened new positions — a net loss of 13 holders — while 48 trimmed existing stakes and 45 added.
The largest buyer was JW Asset Management, opening a new position worth an estimated $3.94M. The largest seller was Franklin Resources, cutting an estimated $7.87M.
- 149 institutional investors held Heron Therapeutics (HRTX) as of Q2 2023, down from 162 in Q1 2023.
- Funds reported $115M of Heron Therapeutics stock for Q2 2023, down 30% quarter-over-quarter.
- 16 funds opened new Heron Therapeutics positions in Q2 2023 and 29 closed out, a net change of -13 holders.
- The largest Heron Therapeutics buyer in Q2 2023 was JW Asset Management, an estimated $3.94M added.
- The largest Heron Therapeutics seller in Q2 2023 was Franklin Resources, an estimated $7.87M sold.
Based on aggregated 13F filings for Q2 2023.